NYSE:EWMedical Equipment
Edwards Lifesciences (EW) Is Down 6.2% After Margin-Squeezing 2025 Results And Cautious 2026 EPS Outlook
In the past week, Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full-year 2025 sales of US$6.07 billion, alongside issuing 2026 guidance calling for first-quarter sales of US$1.55 billion to US$1.63 billion and full-year EPS of US$2.90 to US$3.05.
While revenue continued to grow, the sharp drop in quarterly and full-year net income and EPS highlights how margin pressure and one-off factors are shaping Edwards’ profit profile as it invests behind its Structural Heart...